Shad B Smith

Dr. Shad B Smith

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2013 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
LDLuda Diatchenko
Luda Diatchenko
RFRoger B Fillingim
Roger B Fillingim
SSShad B Smith
Shad B Smith
WMWilliam Maixner
William Maixner

1 November 2011 in The Journal of Pain
Verified
Journal Article
Closed access
SSShad B Smith
Shad B Smith
DMDylan W. Maixner
Dylan W. Maixner
JGJoel D. Greenspan
Joel D. Greenspan
RDRonald Dubner
Ronald Dubner
RFRoger B Fillingim
Roger B Fillingim
LDLuda Diatchenko
Luda Diatchenko

1 April 2010 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
ITInna E. Tchivileva
Inna E. Tchivileva
PLPei Feng Lim
Pei Feng Lim
SSShad B Smith
Shad B Smith
GSGary D. Slade
Gary D. Slade
LDLuda Diatchenko
Luda Diatchenko
WMWilliam Maixner
William Maixner
Introduction Three common haplotypes in the gene encoding catechol-O-methyltransferase (COMT) have been associated with pain modulation and the risk of developing chronic musculoskeletal pain, namely temporomandibular disorder (TMD). Haplotypes coding for higher enzymatic activity were correlated with lower pain perception. Rodent studies showed that COMT inhibition increases pain sensitivity through β2/3-adrenergic receptors. We hypothesized that the nonselective β-adrenergic antagonist propranolol will reduce clinical and experimental pain in TMD patients in a manner dependent on the individuals' COMT diplotype. Methods Forty Caucasian female participants meeting the Research Diagnostic Criteria for TMD were genotyped for COMT polymorphisms and completed a randomized, double-blind, placebo-controlled, two-period crossover pilot study. Each period consisted of a baseline assessment week followed by an intervention week (propranolol or placebo). Changes in clinical pain ratings, psychological status, and responses to heat and pressure stimuli between baseline and intervention weeks were compared across periods. Results The number of patients reporting a reduction in pain intensity rating was greater during propranolol treatment (P=0.014) compared with placebo. Propranolol significantly reduced a composite pain index (P=0.02) but did not decrease other clinical and experimental pain ratings. When stratified by the COMT high activity haplotype, a beneficial effect of propranolol on pain perception was noted in patients not carrying this haplotype, a diminished benefit was observed in the heterozygotes, and no benefit was noted in the homozygotes. Conclusion COMT haplotypes may serve as genetic predictors of propranolol treatment outcome, identifying a subgroup of TMD patients who will benefit from propranolol therapy.

8 September 2011 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
SSShad B Smith
Shad B Smith
DMDylan W. Maixner
Dylan W. Maixner
RFRoger B Fillingim
Roger B Fillingim
GSGary Slade
Gary Slade
RGRichard H. Gracely
Richard H. Gracely
LDLuda Diatchenko
Luda Diatchenko
Objective: Fibromyalgia (FM) represents a complex disorder that is characterized by widespread pain and tenderness and is frequently accompanied by additional somatic and cognitive/affective symptoms. Genetic risk factors are known to contribute to the etiology of the syndrome. The aim of this study was to examine >350 genes for association with FM, using a large‐scale candidate gene approach.Methods: The study group comprised 496 patients with FM (cases) and 348 individuals with no chronic pain (controls). Genotyping was performed using a dedicated gene array chip, the Pain Research Panel, which assays variants characterizing >350 genes known to be involved in the biologic pathways relevant to nociception, inflammation, and mood. Association testing was performed using logistic regression.Results: Significant differences in allele frequencies between cases and controls were observed for 3 genes: GABRB3 (rs4906902; P = 3.65 × 10−6), TAAR1 (rs8192619; P = 1.11 × 10−5), and GBP1 (rs7911; P = 1.06 × 10−4). These 3 genes and 7 other genes with suggestive evidence for association were examined in a second, independent cohort of patients with FM and control subjects who were genotyped using the Perlegen 600K platform. Evidence of association in the replication cohort was observed for TAAR1, RGS4, CNR1, and GRIA4.Conclusion: Variation in these 4 replicated genes may serve as a basis for development of new diagnostic approaches, and the products of these genes may contribute to the pathophysiology of FM and represent potential targets for therapeutic action.

1 February 2010 in The Clinical Journal of Pain
Verified
Journal Article
Closed access
PLPei Feng Bds Lim
Pei Feng Bds Lim
SSShad B Smith
Shad B Smith
KBKanokporn Dds Bhalang
Kanokporn Dds Bhalang
GSGary D. Bdsc Slade
Gary D. Bdsc Slade
WMWilliam Dds Maixner
William Dds Maixner
Objectives The aim of this study is to examine the difference in the report of bodily pain experienced by patients who develop temporomandibular disorders (TMD) and by those who do not develop TMD over a 3-year observation period. Methods This is a 3-year prospective study of 266 females aged 18 to 34 years initially free of TMD pain. All patients completed the Symptom Report Questionnaire (SRQ) at baseline and yearly intervals, and at the time they developed TMD (if applicable). The SRQ is a self-report instrument evaluating the extent and location of pain experienced in the earlier 6 months. Statistical analysis was carried out using repeated measures ANOVA. Results Over the 3-year period, 16 patients developed TMD based on the Research Diagnostic Criteria for TMD. Participants who developed TMD reported more headaches (P=0.0089), muscle soreness or pain (P=0.005), joint soreness or pain (P=0.0012), back pain (P=0.0001), chest pain (P=0.0004), abdominal pain (P=0.0021), and menstrual pain (P=0.0036) than Participants who did not develop TMD at both the baseline and final visits. Participants who developed TMD also reported significantly more headache (P=0.0006), muscle soreness or pain (P=0.0059), and other pains (P=0.0188) when they were diagnosed with TMD compared with the baseline visit. Discussion The development of TMD was accompanied by increases in headaches, muscle soreness or pain, and other pains that were not observed in the Participants who did not develop TMD. Participants who developed TMD also report higher experience of joint, back, chest, and menstrual pain at baseline.

1 September 2006 in Pain
Verified
Journal Article
Closed access
AGAmanda D. Green
Amanda D. Green
KYKatrina K. Young
Katrina K. Young
SLSonya G. Lehto
Sonya G. Lehto
SSShad B Smith
Shad B Smith
JMJeffrey S. Mogil
Jeffrey S. Mogil
Itch features considerable interindividual variability in humans, and initial studies using animal models have demonstrated a likely role of genetic factors in mediating such variability. In an attempt to systematically study genetic mediation of itch in the mouse such that gene identification by linkage mapping might be achieved, we examined scratching behavior induced by histamine and chloroquine in mice of 11 inbred mouse strains. Multiple chloroquine drug doses were used, revealing the existence of inverted-U dose-response relationships in every strain, allowing us to determine strain-dependent peak scratching behavior over the entire dose range. Peak chloroquine-induced scratching varied by 2.5-fold in this set of strains; scratching behavior shows moderate heritability in the mouse. The present data also reveal, for the first time, significant sex differences in pruritogen-induced scratching behavior, with female mice scratching an average of 23% more than males. Finally, a comparison of the strain means obtained here with previously collected data using nociceptive assays revealed a suggestive negative genetic correlation between chloroquine-induced itch and thermal pain, such that strains sensitive to pain are resistant to itch and vice versa. This finding may have implications both for our understanding of itch pathophysiology and for the identification of itch-related genes.